WB, ChIP
H Mk
Endogenous
300
Rabbit IgG
#Q96L73
64324
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Chromatin IP | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human NSD1 protein.
Background
Nuclear receptor SET domain-containing protein 1 (NSD1) is a member of the NSD family of histone methyltransferases, including WHSC1/NSD2 and WHSC1L1/NSD3. NSD1 specifically catalyzes mono- and di-methylation of histone H3 at Lys36 (H3K36me), a mark that is typically associated with transcriptionally active regions of the genome (1,2). NSD1 is expressed as two isoforms: a predominantly expressed short isoform of roughly 2,400 amino acids, and a less abundant long isoform of nearly 2,700 amino acids (3). NSD1 is required for proper embryonic development, as deletion of NSD1 is embryonic lethal in mice (4). Mutations in NSD1 are also believed to be the major cause of Sotos syndrome, an overgrowth disorder characterized by pre- and post-natal overgrowth, macrocephaly, advanced bone age, and developmental delay (5-7). NSD1 mutations have additionally been documented in two related overgrowth disorders, Weaver syndrome and Beckwith-Wiedemann syndrome, albeit less frequently (6-8). NSD1 is also mutated or has altered expression in several types of cancer. For instance, NSD1 is upregulated in metastatic prostate cancer and hepatocellular carcinoma (HCC) compared to healthy tissue (9,10). Loss-of-function mutations have also been observed for NSD1 in head and neck squamous cell carcinomas (HNSCCs), and the NSD1 gene is epigenetically silenced in neuroblastoma and glioma cells (11,12). NSD1, therefore, appears to exert tumor suppressive or promoting functions depending on cellular context, either through promoting the expression of tumor suppressor or oncogenic proteins, respectively (13).
- Wagner, E.J. and Carpenter, P.B. (2012) Nat Rev Mol Cell Biol 13, 115-26.
- Bennett, R.L. et al. (2017) Cold Spring Harb Perspect Med 7, a026708. doi: 10.1101/cshperspect.a026708.
- Lucio-Eterovic, A.K. et al. (2010) Proc Natl Acad Sci U S A 107, 16952-7.
- Rayasam, G.V. et al. (2003) EMBO J 22, 3153-63.
- Kurotaki, N. et al. (2002) Nat Genet 30, 365-6.
- Douglas, J. et al. (2003) Am J Hum Genet 72, 132-43.
- Rio, M. et al. (2003) J Med Genet 40, 436-40.
- Baujat, G. et al. (2004) Am J Hum Genet 74, 715-20.
- Bianco-Miotto, T. et al. (2010) Cancer Epidemiol Biomarkers Prev 19, 2611-22.
- Zhang, S. et al. (2019) J Exp Clin Cancer Res 38, 467.
- (2015) Nature 517, 576-82.
- Berdasco, M. et al. (2009) Proc Natl Acad Sci U S A 106, 21830-5.
- Krossa, I. et al. (2022) Cancers (Basel) 14, 4865. doi: 10.3390/cancers14194865.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting ChIP: Chromatin IP
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.